In CRC, the infiltration of CD206+CD163+ M2-TAMs is dramatically higher in oxaliplatin-resistant patients, which enables oxaliplatin resistance through METTL3-mediated m6A modification on TRAF5 mRNAs (27). Here, METTL3 is linked to colorectal carcinoma.